• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc. (Amendment)

    2/9/23 11:12:40 AM ET
    $BIO.B
    Get the next $BIO.B alert in real time by email
    SC 13G/A 1 tv0417-bioradlaboratoriesinc.htm SCHEDULE 13G/A bioradlaboratoriesincclassa

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Bio-Rad Laboratories Inc. Class A

    Title of Class of Securities:  Common Stock

    CUSIP Number:  090572207

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  090572207

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    30,044

    7.  SOLE DISPOSITIVE POWER

    2,302,671

    8.  SHARED DISPOSITIVE POWER

    88,765

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,391,436

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.66%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Bio-Rad Laboratories Inc. Class A

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1000 Alfred Nobel Drive
    Hercules, CA 94547

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    090572207

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $BIO.B alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIO.B

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIO.B
    SEC Filings

    View All

    SEC Form 144 filed by Bio-Rad Laboratories Inc.

    144 - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/6/25 4:24:39 PM ET
    $BIO.B

    SEC Form 10-Q filed by Bio-Rad Laboratories Inc.

    10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/29/25 4:18:31 PM ET
    $BIO.B

    Bio-Rad Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/29/25 4:16:49 PM ET
    $BIO.B

    $BIO.B
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, President, LSG Barry James sold $214,289 worth of Bio-Rad A Common Stock (700 units at $306.18), decreasing direct ownership by 58% to 510 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    11/10/25 4:15:49 PM ET
    $BIO.B

    President & COO Divincenzo Jonathan P. converted options into 1,869 units of Bio-Rad A Common Stock and covered exercise/tax liability with 950 units of Bio-Rad A Common Stock (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/28/25 12:29:44 PM ET
    $BIO.B

    EVP, Global Supply Chain Evran Sedat converted options into 1,044 units of Bio-Rad A Common Stock and covered exercise/tax liability with 335 units of Bio-Rad A Common Stock, increasing direct ownership by 47% to 2,233 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/21/25 4:42:00 PM ET
    $BIO.B

    $BIO.B
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits

    SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer. The Element AVITI Sequencing Platform's novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuo

    2/8/23 8:00:00 AM ET
    $BIO
    $BIO.B
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO.B
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Rad Laboratories Inc.

    SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/14/24 5:25:27 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/12/24 1:27:07 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/4/24 11:22:04 AM ET
    $BIO.B